Associations - CD3 agonist

No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
CD19 positive	Acute Lymphocytic Leukemia	CD19 positive	Acute Lymphocytic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	teclistamab Sensitive: A1 - Approval teclistamab Sensitive : A1	teclistamab Sensitive: A1 - Approval teclistamab Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	mosunetuzumab Sensitive: A1 - Approval mosunetuzumab Sensitive : A1	mosunetuzumab Sensitive: A1 - Approval mosunetuzumab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	elranatamab Sensitive: A1 - Approval elranatamab Sensitive : A1	elranatamab Sensitive: A1 - Approval elranatamab Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	glofitamab Sensitive: A1 - Approval glofitamab Sensitive : A1	glofitamab Sensitive: A1 - Approval glofitamab Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	epcoritamab-bysp Sensitive: A1 - Approval epcoritamab-bysp Sensitive : A1	epcoritamab-bysp Sensitive: A1 - Approval epcoritamab-bysp Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	talquetamab Sensitive: A1 - Approval talquetamab Sensitive : A1	talquetamab Sensitive: A1 - Approval talquetamab Sensitive : A1
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A2 - Guideline blinatumomab Sensitive : A2	blinatumomab Sensitive: A2 - Guideline blinatumomab Sensitive : A2
No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2
CD20 positive	B Acute Lymphoblastic Leukemia	CD20 positive	B Acute Lymphoblastic Leukemia	rituximab + blinatumomab Sensitive: A2 - Guideline rituximab + blinatumomab Sensitive : A2	rituximab + blinatumomab Sensitive: A2 - Guideline rituximab + blinatumomab Sensitive : A2
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	HPN-217 Sensitive: B - Late Trials HPN-217 Sensitive : B	HPN-217 Sensitive: B - Late Trials HPN-217 Sensitive : B
CD20 positive	Diffuse Large B Cell Lymphoma	CD20 positive	Diffuse Large B Cell Lymphoma	epcoritamab-bysp Sensitive: C2 – Inclusion Criteria epcoritamab-bysp Sensitive : C2	epcoritamab-bysp Sensitive: C2 – Inclusion Criteria epcoritamab-bysp Sensitive : C2
CD20 positive	Follicular Lymphoma	CD20 positive	Follicular Lymphoma	epcoritamab-bysp Sensitive: C2 – Inclusion Criteria epcoritamab-bysp Sensitive : C2	epcoritamab-bysp Sensitive: C2 – Inclusion Criteria epcoritamab-bysp Sensitive : C2
CLDN6 expression	Non Small Cell Lung Cancer	CLDN6 expression	Non Small Cell Lung Cancer	AMG 794 Sensitive: C2 – Inclusion Criteria AMG 794 Sensitive : C2	AMG 794 Sensitive: C2 – Inclusion Criteria AMG 794 Sensitive : C2
CLDN6 expression	Ovarian Cancer	CLDN6 expression	Ovarian Cancer	AMG 794 Sensitive: C2 – Inclusion Criteria AMG 794 Sensitive : C2	AMG 794 Sensitive: C2 – Inclusion Criteria AMG 794 Sensitive : C2
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	blinatumomab Sensitive: C2 – Inclusion Criteria blinatumomab Sensitive : C2	blinatumomab Sensitive: C2 – Inclusion Criteria blinatumomab Sensitive : C2
CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	ASP2138 Sensitive: C2 – Inclusion Criteria ASP2138 Sensitive : C2	ASP2138 Sensitive: C2 – Inclusion Criteria ASP2138 Sensitive : C2
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	ASP2138 Sensitive: C2 – Inclusion Criteria ASP2138 Sensitive : C2	ASP2138 Sensitive: C2 – Inclusion Criteria ASP2138 Sensitive : C2
CD22 positive	B Acute Lymphoblastic Leukemia	CD22 positive	B Acute Lymphoblastic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria blinatumomab + inotuzumab ozogamicin Sensitive : C2	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria blinatumomab + inotuzumab ozogamicin Sensitive : C2
CD22 expression	B Acute Lymphoblastic Leukemia	CD22 expression	B Acute Lymphoblastic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria blinatumomab + inotuzumab ozogamicin Sensitive : C2	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria blinatumomab + inotuzumab ozogamicin Sensitive : C2
DLL3 expression	Small Cell Lung Cancer	DLL3 expression	Small Cell Lung Cancer	AMG 757 Sensitive: C3 – Early Trials AMG 757 Sensitive : C3	AMG 757 Sensitive: C3 – Early Trials AMG 757 Sensitive : C3
Chr t(14;21)(q22;q22)	Acute Myelogenous Leukemia	Chr t(14;21)(q22;q22)	Acute Myelogenous Leukemia	MGD006 Sensitive: C3 – Early Trials MGD006 Sensitive : C3	MGD006 Sensitive: C3 – Early Trials MGD006 Sensitive : C3
BCR-ABL1 E255K	Acute Lymphocytic Leukemia	BCR-ABL1 E255K	Acute Lymphocytic Leukemia	dasatinib + blinatumomab Sensitive: C3 – Early Trials dasatinib + blinatumomab Sensitive : C3	dasatinib + blinatumomab Sensitive: C3 – Early Trials dasatinib + blinatumomab Sensitive : C3
BCR-ABL1 D276G	Acute Lymphocytic Leukemia	BCR-ABL1 D276G	Acute Lymphocytic Leukemia	dasatinib + blinatumomab Sensitive: C3 – Early Trials dasatinib + blinatumomab Sensitive : C3	dasatinib + blinatumomab Sensitive: C3 – Early Trials dasatinib + blinatumomab Sensitive : C3
IL17A rs3819024	Acute Lymphocytic Leukemia	IL17A rs3819024	Acute Lymphocytic Leukemia	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3
PAK4 deletion	B Acute Lymphoblastic Leukemia	PAK4 deletion	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3
CDKN2A deletion	B Acute Lymphoblastic Leukemia	CDKN2A deletion	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3

CD3 agonist

CD3 agonist

Associations(112)

Associations
(112)